 |
41 Diseases |  |
6 Trials |
|
6 Trials |  |
57 News |  |
- | Xolair (omalizumab) / Roche, Novartis
Journal: Evaluating the affordability of asthma, chronic obstructive pulmonary disease, and cystic fibrosis medicines in a middle-income country. (Pubmed Central) - Nov 5, 2023
Results showed that the existing insurance coverage does not protect households from hardship, so more considerations are needed such as different insurance schedules and patient support programs.
- || budesonide inhalation solution (AQ001S) / Aquilon
Trial completion: BOREAS: Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics (clinicaltrials.gov) - Jun 9, 2023
P1/2, N=23, Completed, Sponsor: Aquilon Pharmaceuticals S.A.
Results showed that the existing insurance coverage does not protect households from hardship, so more considerations are needed such as different insurance schedules and patient support programs. Recruiting --> Completed
- | Curosurf (poractant alfa) / Chiesi
Trial completion date, Trial primary completion date: The Budesonide in Babies (BiB) Trial (clinicaltrials.gov) - May 9, 2023
P3, N=1160, Recruiting, Sponsor: NICHD Neonatal Research Network
Recruiting --> Completed Trial completion date: Sep 2025 --> Sep 2027 | Trial primary completion date: Mar 2023 --> Sep 2025
- | budesonide inhalation solution (AQ001S) / Aquilon
Trial completion date, Trial primary completion date: BOREAS: Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics (clinicaltrials.gov) - Nov 3, 2022
P1/2, N=24, Recruiting, Sponsor: Aquilon Pharmaceuticals S.A.
Trial completion date: Sep 2025 --> Sep 2027 | Trial primary completion date: Mar 2023 --> Sep 2025 Trial completion date: May 2022 --> Jan 2023 | Trial primary completion date: May 2022 --> Jan 2023
- | formoterol fumarate / Generic mfg., budesonide inhalation suspension / Generic mfg.
Enrollment status, Trial primary completion date: ARrest RESpiraTory Failure From PNEUMONIA (clinicaltrials.gov) - Aug 10, 2022
P3, N=600, Recruiting, Sponsor: Stanford University
Trial completion date: May 2022 --> Jan 2023 | Trial primary completion date: May 2022 --> Jan 2023 Enrolling by invitation --> Recruiting | Trial primary completion date: Aug 2024 --> Jul 2025
- | formoterol fumarate / Generic mfg., budesonide inhalation suspension / Generic mfg.
Trial completion date, Trial primary completion date: ARrest RESpiraTory Failure From PNEUMONIA (clinicaltrials.gov) - Jul 6, 2022
P3, N=600, Enrolling by invitation, Sponsor: Stanford University
Enrolling by invitation --> Recruiting | Trial primary completion date: Aug 2024 --> Jul 2025 Trial completion date: Jun 2024 --> Aug 2025 | Trial primary completion date: Apr 2024 --> Aug 2024
- || budesonide inhalation solution (AQ001S) / Aquilon
Trial completion, Enrollment change: BORA: Single-dose AQ001S PK Study in Healthy Volunteers (clinicaltrials.gov) - Feb 21, 2022
P1, N=29, Completed, Sponsor: Aquilon Pharmaceuticals S.A.
Trial completion date: Jun 2024 --> Aug 2025 | Trial primary completion date: Apr 2024 --> Aug 2024 Recruiting --> Completed | N=20 --> 29
- | budesonide inhalation solution (AQ001S) / Aquilon
Trial completion date, Trial primary completion date: BOREAS: Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics (clinicaltrials.gov) - Feb 15, 2022
P1/2, N=24, Recruiting, Sponsor: Aquilon Pharmaceuticals S.A.
Recruiting --> Completed | N=20 --> 29 Trial completion date: Nov 2021 --> May 2022 | Trial primary completion date: Nov 2021 --> May 2022
- || budesonide inhalation suspension / Generic mfg., montelukast / Generic mfg.
Clinical, Journal: Treatment of pediatric mild persistent asthma with low-dose budesonide inhalation suspension vs. montelukast in China. (Pubmed Central) - Jan 27, 2022
Trial completion date: Nov 2021 --> May 2022 | Trial primary completion date: Nov 2021 --> May 2022 Both treatments provided acceptable overall asthma control in children with mild persistent asthma; however, more reliever medication and more medical expenditures attributable to asthma were needed for BIS vs. montelukast in real-world settings, where factors such as compliance were also taken into account.
- || budesonide inhalation solution (AQ001S) / Aquilon
New P1 trial: BORA: Single-dose AQ001S PK Study in Healthy Volunteers (clinicaltrials.gov) - Dec 7, 2021
P1, N=20, Recruiting, Sponsor: Aquilon Pharmaceuticals S.A.
- || montelukast / Generic mfg.
Clinical, Journal, HEOR: Cost-effectiveness analysis of double low-dose budesonide and low-dose budesonide plus montelukast among pediatric patients with persistent asthma receiving Step 3 treatment in China. (Pubmed Central) - Oct 1, 2021
Sensitivity analyses supported the robustness of the results and the generalizability of findings across geographic regions in China. The cost-effectiveness analysis suggests that double low-dose budesonide is a dominant Step 3 treatment strategy compared with low-dose budesonide plus montelukast for patients aged 1 to 5 years with persistent asthma in China.
- || Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion
Trial completion: BLANC: To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years. (clinicaltrials.gov) - Sep 2, 2021
P1, N=12, Completed, Sponsor: Bond Avillion 2 Development LP
The cost-effectiveness analysis suggests that double low-dose budesonide is a dominant Step 3 treatment strategy compared with low-dose budesonide plus montelukast for patients aged 1 to 5 years with persistent asthma in China. Recruiting --> Completed
- || budesonide inhalation solution (AQ001S) / Aquilon
Enrollment open: BOREAS: Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics (clinicaltrials.gov) - Jul 27, 2021
P1/2, N=24, Recruiting, Sponsor: Aquilon Pharmaceuticals S.A.
Recruiting --> Completed Not yet recruiting --> Recruiting
- || budesonide inhalation suspension / Generic mfg.
Clinical, Journal: The impact of budesonide inhalation suspension for asthma hospitalization: In terms of length of stay, recovery time from symptoms, and hospitalization costs. (Pubmed Central) - Jul 11, 2021
Not yet recruiting --> Recruiting BIS may contribute to shorten length of hospital stay and to reduce symptoms and medical expenditure irrespective of the presence or absence of respiratory infection.
- | budesonide inhalation solution (AQ001S) / Aquilon
New P1/2 trial: BOREAS: Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics (clinicaltrials.gov) - Jun 21, 2021
P1/2, N=24, Not yet recruiting, Sponsor: Aquilon Pharmaceuticals S.A.
- || budesonide inhalation suspension / Generic mfg., fluticasone / Generic mfg.
Clinical, Journal: Relationship between interleukin-13 rs20541 single nucleotide polymorphisms and therapeutic efficacy in children with asthma. (Pubmed Central) - May 15, 2021
Polymorphism of the IL-13 rs20541 locus may be correlated with therapeutic efficacy. Patients carrying the GG allele were more responsive than their counterparts with the GA or AA allele.
- || Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion
Enrollment open: BLANC: To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years. (clinicaltrials.gov) - May 11, 2021
P1, N=10, Recruiting, Sponsor: Bond Avillion 2 Development LP
Patients carrying the GG allele were more responsive than their counterparts with the GA or AA allele. Not yet recruiting --> Recruiting
- || Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion
New P1 trial: BLANC: To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years. (clinicaltrials.gov) - Apr 18, 2021
P1, N=10, Not yet recruiting, Sponsor: Bond Avillion 2 Development LP
- | Curosurf (poractant alfa) / Chiesi
Enrollment open: The Budesonide in Babies (BiB) Trial (clinicaltrials.gov) - Mar 25, 2021
P3, N=1160, Recruiting, Sponsor: NICHD Neonatal Research Network
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Yupelri (revefenacin) / Theravance Biopharma, Mylan
[VIRTUAL] Physicochemical Stability and Compatibility of Long-Acting Muscarinic Antagonist Revefenacin Inhalation Solution and Inhaled Corticosteroid Budesonide Inhalation Suspension () - Mar 14, 2021 - Abstract #ATS2021ATS_3524;
CONCLUSIONS Our results demonstrate the physicochemical compatibility and stability of the admixture of revefenacin inhalation solution and budesonide inhalation suspension for up to 24 hours at room temperature. Further study is required to evaluate the clinical safety and efficacy of these medicines in admixture.
- | Curosurf (poractant alfa) / Chiesi
Trial initiation date: The Budesonide in Babies (BiB) Trial (clinicaltrials.gov) - Feb 16, 2021
P3, N=1160, Not yet recruiting, Sponsor: NICHD Neonatal Research Network
Further study is required to evaluate the clinical safety and efficacy of these medicines in admixture. Initiation date: Dec 2020 --> Mar 2021
- | Curosurf (poractant alfa) / Chiesi
Trial initiation date: The Budesonide in Babies (BiB) Trial (clinicaltrials.gov) - Dec 4, 2020
P3, N=1160, Not yet recruiting, Sponsor: NICHD Neonatal Research Network
Initiation date: Dec 2020 --> Mar 2021 Initiation date: Sep 2020 --> Dec 2020
- | Curosurf (poractant alfa) / Chiesi
New P3 trial: The Budesonide in Babies (BiB) Trial (clinicaltrials.gov) - Sep 11, 2020
P3, N=1160, Not yet recruiting, Sponsor: NICHD Neonatal Research Network
- | formoterol fumarate / Generic mfg., budesonide inhalation suspension / Generic mfg.
Enrollment status: ARrest RESpiraTory Failure From PNEUMONIA (clinicaltrials.gov) - Aug 11, 2020
P3, N=600, Enrolling by invitation, Sponsor: Stanford University
Initiation date: Sep 2020 --> Dec 2020 Recruiting --> Enrolling by invitation
- | formoterol fumarate / Generic mfg., budesonide inhalation suspension / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: ARrest RESpiraTory Failure From PNEUMONIA (clinicaltrials.gov) - May 28, 2020
P3, N=600, Recruiting, Sponsor: Stanford University
Recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting | Trial completion date: Nov 2024 --> May 2024 | Trial primary completion date: Sep 2024 --> Mar 2024
- | formoterol fumarate / Generic mfg., budesonide inhalation suspension / Generic mfg.
New P3 trial: ARrest RESpiraTory Failure From PNEUMONIA (clinicaltrials.gov) - Dec 9, 2019
P3, N=600, Not yet recruiting, Sponsor: Stanford University
- | budesonide inhalation (VR647) / Vectura
New P1 trial: A Comparison of VR647 and Conventionally Nebulized Budesonide in Healthy Volunteers and Adult Asthma Subjects (clinicaltrials.gov) - Jul 24, 2019
P1, N=34, Completed, Sponsor: Vectura Limited
- | budesonide inhalation suspension / Generic mfg.
New P3 trial: Efficacy and Safety of Budesonide Inhalation Suspension for the Treatment of Chronic Rhinosinusitis With Polyposis. (clinicaltrials.gov) - Sep 26, 2018
P3, N=91, Completed, Sponsor: Beijing Tongren Hospital
- | budesonide inhalation (VR647) / Vectura
Trial completion, Enrollment change: A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma (clinicaltrials.gov) - Jul 11, 2018
P1, N=17, Completed, Sponsor: Vectura Limited
Not yet recruiting --> Recruiting | Trial completion date: Nov 2024 --> May 2024 | Trial primary completion date: Sep 2024 --> Mar 2024 Recruiting --> Completed | N=12 --> 17
- | budesonide inhalation (VR647) / Vectura
New P1 trial: A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma (clinicaltrials.gov) - Feb 5, 2018
P1, N=12, Recruiting, Sponsor: Vectura Limited
- | budesonide inhalation suspension / Generic mfg.
Trial completion, Enrollment change: Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial (clinicaltrials.gov) - Feb 17, 2017
P1, N=36, Completed, Sponsor: Vanderbilt University
Recruiting --> Completed | N=12 --> 17 Active, not recruiting --> Completed | N=30 --> 36
- budesonide inhalation suspension / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial (clinicaltrials.gov) - Nov 8, 2016
P1, N=30, Active, not recruiting, Sponsor: Vanderbilt University
Active, not recruiting --> Completed | N=30 --> 36 Recruiting --> Active, not recruiting | N=20 --> 30 | Trial primary completion date: Sep 2016 --> Dec 2016
- fluticasone / Generic mfg.
Trial completion, Enrollment change, Surgery: Comparison of Nasal Steroids After FESS in CRSwNP (clinicaltrials.gov) - Jul 13, 2016
P=N/A, N=32, Completed, Sponsor: Yale University
Recruiting --> Active, not recruiting | N=20 --> 30 | Trial primary completion date: Sep 2016 --> Dec 2016 Recruiting --> Completed | N=60 --> 32
- budesonide inhalation suspension / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date, Surgery: Trial of Directed High-dose Nasal Steroids on Residual Smell Loss in Sinus Patients After Sinus Surgery (clinicaltrials.gov) - Apr 7, 2016
P2, N=0, Withdrawn, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed | N=60 --> 32 N=70 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Mar 2014 --> Nov 2013
- | budesonide inhalation suspension / Generic mfg.
New P4 trial, Surgery: Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD (clinicaltrials.gov) - Jul 22, 2015
P4, N=73, Not yet recruiting, Sponsor: Xiuyi Zhi
- budesonide inhalation suspension / Generic mfg.
Trial primary completion date: Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial (clinicaltrials.gov) - Apr 18, 2015
P1, N=20, Recruiting, Sponsor: Vanderbilt University
N=70 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Mar 2014 --> Nov 2013 Trial primary completion date: Nov 2015 --> Sep 2016
- ||| fluticasone / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date, Surgery: Comparison of Nasal Steroids After FESS in CRSwNP (clinicaltrials.gov) - Jan 26, 2015
P=N/A, N=60, Recruiting, Sponsor: Yale University
Trial primary completion date: Nov 2015 --> Sep 2016 Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Jan 2015 | Trial primary completion date: Jan 2015 --> Jul 2015
- | budesonide inhalation suspension / Generic mfg.
Trial completion, Trial primary completion date: Effects and Safety of Budesonide Inhalation Suspension Via Transnasal Nebulization in Nasal Polyps (clinicaltrials.gov) - Oct 11, 2014
P2/3, N=57, Completed, Sponsor: Beijing Tongren Hospital
Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Jan 2015 | Trial primary completion date: Jan 2015 --> Jul 2015 Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2011
- fluticasone / Generic mfg.
Surgery: Comparison of Nasal Steroids After FESS in CRSwNP (clinicaltrials.gov) - Jul 18, 2014
P=N/A, N=60, Not yet recruiting, Sponsor: Yale University
- budesonide inhalation suspension / Generic mfg.
New P1 trial: Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial (clinicaltrials.gov) - Jul 12, 2014
P1, N=20, Recruiting, Sponsor: Vanderbilt University
- || budesonide inhalation suspension / Generic mfg.
New P2/3 trial: Effects and Safety of Budesonide Inhalation Suspension Via Transnasal Nebulization in Nasal Polyps (clinicaltrials.gov) - Dec 29, 2013
P2/3, N=60, Recruiting, Sponsor: Beijing Tongren Hospital
- | budesonide inhalation suspension / Generic mfg.
New P2 trial, Surgery: Trial of Directed High-dose Nasal Steroids on Residual Smell Loss in Sinus Patients After Sinus Surgery (clinicaltrials.gov) - Mar 18, 2013
P2, N=70, Recruiting, Sponsor: University of North Carolina, Chapel Hill
- || budesonide inhalation suspension / Generic mfg.
Enrollment change: Pulmicort Respules 0.25/0.5 Specific Clinical Experience Investigation (clinicaltrials.gov) - Jan 22, 2013
P=N/A, N=633, Completed, Sponsor: AstraZeneca
Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2011 N=400 --> 633
- ||| budesonide inhalation suspension / Generic mfg.
Trial completion: Pulmicort Respules 0.25/0.5 Specific Clinical Experience Investigation (clinicaltrials.gov) - Jan 22, 2013
P=N/A, N=633, Completed, Sponsor: AstraZeneca
N=400 --> 633 Active, not recruiting --> Completed
- budesonide inhalation suspension / Generic mfg.
Trial withdrawal: Budesonide: Pulmicort Respules on Relapse Rates After Treatment in the ED (clinicaltrials.gov) - Sep 1, 2011
P4, N=0, Withdrawn, Sponsor: Phoenix Children's Hospital
Active, not recruiting --> Completed Terminated --> Withdrawn